Investigational drug · Phase 3
GP681
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Influenza, Human, Influenza.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "GP681"
First trial start
2024
Nov 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GP681", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza, Human
- Influenza
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "GP681" as an intervention, largest first.
- Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against InfluenzaPivotal-lookingRecruiting
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT06574503 · 748 participants (planned) · Start Dec 1, 2024 · Primary completion Jul 30, 2027
Drug: GP681 40mg; GP681 Simulant · For: Influenza
Sites: Hanzhou, China
- To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus InfectionPivotal-lookingCompleted
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT05474755 · 591 participants · Start Jul 28, 2022 · Primary completion Apr 25, 2023
Drug: GP681 40mg; Placebo · For: Influenza
Sites: Wenling, China
- Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza ComplicationsPivotal-lookingRecruiting
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT06573008 · 328 participants (planned) · Start Nov 11, 2024 · Primary completion Dec 30, 2025
Drug: GP681 40mg; GP681 Simulant · For: Influenza, Human
Sites: Chizhou, China
- A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute InfluenzaPivotal-lookingCompleted
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT04736758 · 216 participants · Start Jan 8, 2021 · Primary completion Dec 18, 2021
Drug: GP681 tablet; GP681 Simulant · For: Influenza
Sites: Nanchang, China
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT04729764 · 56 participants · Start Aug 27, 2020 · Primary completion Dec 15, 2020
Drug: GP681 Tablet · For: Influenza
Sites: Shanghai, China
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT05789342 · 54 participants · Start Feb 15, 2023 · Primary completion Sep 11, 2023
Drug: GP681; Rosuvastatin and 3 more · For: Healthy Volunteers
Sites: Beijing, China
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT06643156 · 44 participants · Start Sep 27, 2024 · Primary completion Jan 18, 2025
Drug: GP681 10mg/20mg/40mg · For: Influenza
Sites: Ningbo, China
- Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male SubjectsCompleted
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT06678542 · 36 participants · Start Sep 27, 2024 · Primary completion Feb 16, 2025
Drug: GP681 tablet; GP681 Powder for Oral Suspension · For: Healthy Participants
Sites: Ningbo, China
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT05814926 · 24 participants · Start Apr 26, 2023 · Primary completion Aug 3, 2023
Drug: GP681 · For: Healthy Volunteers; Hepatic Impairment
Sites: Beijing, China
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
NCT05103241 · 6 participants · Start Oct 26, 2021 · Primary completion Nov 22, 2021
Drug: [14C] GP681 · For: Healthy Volunteers
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- A phase I study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of suraxavir marboxil: a novel oral antiviral for influenza.
Zhou J, Yan S, Zhao Y, et al. · Antimicrob Agents Chemother 2026
- [Annual review of community-acquired pneumonia (CAP) 2025].
Zhou F, Liu ZP, Cao B · Zhonghua Jie He He Hu Xi Za Zhi 2026
- Physiologically based pharmacokinetic (PBPK) modeling of drug-drug interactions between suraxavir marboxil and CYP3A4 inhibitors: Quantitative prediction of pharmacokinetic effects on active metabolite GP1707D07.
Yang L, Yang F, Shen CZ, et al. · Pharm Sci Adv 2025
- A first-in-human phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel anti-influenza agent suraxavir marboxil in healthy Chinese subjects.
Wu Q, Lv L, Yan S, et al. · Antimicrob Agents Chemother 2025
- Efficacy and safety of single-dose suraxavir marboxil tablet in the treatment of acute uncomplicated influenza in adults: a multi-centre, randomized, double-blind, placebo-controlled phase 2 clinical trial.
Wang Y, Wang H, Liu D, et al. · Clin Microbiol Infect 2025
- Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism.
Han M, Cui G, Zhao Y, et al. · Front Pharmacol 2024
Also in development for Influenza, Human
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- Flu mRNAGSK6479720A, GSK6498032APhase 22 trials
GSK · Influenza, Human
- ARCT-2304Phase 21 trial
Arcturus Therapeutics, Inc. · Influenza, Human
- DL001ZF2G22B, F2H23HPhase 21 trial
GSK · Influenza, Human
- DL001Z-NHF2H23D, F2H23BPhase 21 trial
GSK · Influenza, Human
- GSK5800544APhase 21 trial
GSK · Influenza, Human
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.